Topics

Clinical Trials About "Solid Tumor" RSS

16:29 EST 21st January 2020 | BioPortfolio

We list hundreds of Clinical Trials about "Solid Tumor" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "Solid Tumor" on BioPortfolio

We have published hundreds of Solid Tumor news stories on BioPortfolio along with dozens of Solid Tumor Clinical Trials and PubMed Articles about Solid Tumor for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Solid Tumor Companies in our database. You can also find out about relevant Solid Tumor Drugs and Medications on this site too.

Showing "Solid Tumor" Clinical Trials 1–25 of 13,000+

Relevant

ABT-510 and Bevacizumab in Treating Patients With Advanced Solid Tumors

RATIONALE: ABT-510 and bevacizumab may stop the growth of solid tumors by blocking blood flow to the tumor. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Giving ABT-510 together with bevacizumab may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose ...


MAX-10181 Given Orally to Patients With Advanced Solid Tumor

This is a multi-center, first-in-human, non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in patients with advanced solid tumor.

A Study of MORAb-003 in Patients With Solid Tumor

MORAb-003 is intravenously administered to Japanese patients with a folate receptor alpha-expressing solid tumor in order to investigate dose-limiting toxicity and estimate maximum tolerated dose.


A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors

This is a single center、single arm、open-label, to investigate the safety and efficacy of PD-1 and DC-CIK with anti-solid tumor

A Study of AK-01 in Solid Tumors

This two-part study consists of a Phase 1 dose escalation study in participants with locally advanced or metastatic solid tumors, and a Phase 2 portion in up to 3 cohorts with either Small Cell Lung Cancer, Breast Cancer and/or one other solid tumor type

Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)

A Study of Injection HB002.1T in Subjects With Solid Tumor

The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of HB002.1T, a human immunoglobulin Fc fusion protein containing domain 2 and flanking sequence of vascular endothelial growth factor (VEGF) receptor-1 in subjects with solid tumor.

Bevacizumab in Treating Patients With Advanced Solid Tumors

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor . PURPOSE: This phase I trial is studying how well bevacizumab works in treating patients with advanced solid tumors.

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced gynecological solid tumor (Phase 2).

Yoga for Solid Tumor

The purpose of this study is to ascertain the effect of yoga interventions on radiation-related fatigue, and stress in cancer patients with stage I and II solid tumors.

A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation

This is a phase I, open-label, dose escalation study to evaluate tolerability, safety, pharmacokinetics and efficacy in patients with BRAF V600 mutant advanced solid tumor by HL-085 plus Vemurafenib treatment.

Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors

The primary purpose of this study is to evaluate the safety of the tumor-specific TCR-T cells in the treatment of advanced Solid Tumor . The secondary purpose of this study is to preliminarily showed the effect of TCR-T cells in the treatment of advanced Solid Tumor .

GW786034 in Treating Patients With Advanced Solid Tumors

RATIONALE: GW786034 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of GW786034 in treating patients with advanced solid tumors.

Ro 31-7453 in Treating Patients With Locally Advanced or Metastatic Solid Tumor

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of Ro 31-7453 in treating patients who have locally advanced or metastatic solid tumor.

S-3304 in Treating Patients With Advanced Solid Tumors

RATIONALE: S-3304 may stop or slow the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of S-3304 in treating patients who have solid tumors.

Intravital Microscopy in Human Solid Tumors

This study will investigate the tumor-associated vasculature of patients with solid tumors. The investigators will use a technology known as intravital microscopy (IVM) in order to visualize in real-time the vessels associated with solid tumors. The IVM observations may determine if an individual patient's tumor vessels would be amenable to receiving systemic therapy, based on the functionality of the vessels.

Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of docetaxel and oxaliplatin in treating patients who have metastatic or recurrent solid tumor.

MAX-40279-01 in Patients With Advanced Solid Tumors

This is a multi-center, non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-40279-01 in patients with advanced solid tumor.

EMD 121974 in Treating Patients With Advanced Solid Tumors

RATIONALE: EMD 121974 may slow the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of EMD 121974 in treating patients who have advanced solid tumors.

Cetuximab in Treating Patients With Advanced Solid Tumors

RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of cetuximab in treating patients with advanced solid tumors.

Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies

AV-412 is a new oral therapy developed to inhibit the growth of solid tumors in patients who have not responded to standard therapy or surgical interventions, or who have experienced relapse. This study will test the safety of AV-412 and determine the maximum tolerated dose for the treatment of solid tumors.

A Phase 1 Study of HS-10342 In Patients With Advanced Solid Tumor

HS-10342 is a small molecular, oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of HS-10342 in Chinese advanced solid tumor patients. Preliminary efficacy will be also investigated in this study.

Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor

This study will determine the maximum dose of KW-2450 that can be administered safely to subjects with advanced previously treated solid tumor and evaluate its effectiveness.

Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

This protocol will examine the safety of intratumoral administration of Clostridium Novyi-NT spores in patients with treatment-refractory solid tumor malignancies. This investigational study will measure anti-tumor activity of C. novyi-NT administered intratumoral in patients with treatment-refractory solid tumor malignancies.

Immunotherapy for the Treatment of Advanced Solid Tumor

The purpose of this study is to evaluate the safety, side effects and benefits of autologous tumor infiltrating lymphocytes(TIL) specific to personalized Neo-antigens in the treatment of patients with recurrent, metastatic and advanced solid tumors.


More From BioPortfolio on "Solid Tumor"

Quick Search